Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biopharmaceutical company Imugene (ASX:IMU) is on track to start Phase 1 clinical trials for its cancer treatment
  • The CF33 oncolytic virus works to treat cancer by infecting and killing tumour cells while leaving healthy cells unharmed
  • Two batches the cancer treatment were successfully produced to clinical grade GMP, paving the way for Phase 1 trials in 2020
  • There are two constructs of the virus, CheckVacc and Vaxinia, which will be tested in separate trials
  • Imugene shares are down 8.77 per cent, trading for 5.2 cents apiece

Imugene Limited (ASX:IMU) is on track to start Phase 1 clinical trials for its CF33 oncolytic virus technology in 2020.

The Australian-based company specialises in immune-based cancer treatments, developed at the City of Hope Center for Biomedicine and Genetics in California.

Imugene is on track to undertake Phase 1 clinical trials after two batches of the cancer treatment were successfully produced to clinical grade GMP.

The CF33 oncolytic virus is produced in two different constructs: the CheckVacc which is “armed” with an immune checkpoint inhibitor inserted in the virus and the Vaxinia which is “unarmed.”

The company plans to conduct a separate Phase 1 trial for the different constructs at some stage in 2020.

The CF33 oncolytic virus works to treat cancer by infecting tumour cells, before multiplying and ultimately killing them. Pre-clinical trials have shown it is effective on both primary, metastatic and recurring tumours while leaving healthy cells unharmed.

Pre-clinical trials have also shown the CF33 virus technology to effectively shrink tumours at an extremely low dose.

Imugene shares are down 8.77 per cent, trading for 5.2 cents a share at 4:10pm.

IMU by the numbers
More From The Market Herald

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.